Gastric/GEJ cancer: 3rd-line nivolumab boosts OS

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Nivolumab offers improved OS compared with placebo as a third-line therapy for patients with advanced gastric or gastroesophageal junction (GEJ) cancer who are refractory or intolerant to ≥2 lines of chemotherapy.

Why this matters

  • Current guidelines offer no guidance on t...